Profile banner
Fiona Mack

Fiona Mack

Life sciences leader in external innovation and incubator management

Cambridge, Massachusetts
bayer
Houston, Texas
txlifescienceforum+1
Favicon imageresearchgate.net
Favicon imagelinkedin.com

Summary

Bridge between big pharma and early-stage biotech: Fiona has repeatedly led external innovation and incubator initiatives (Roche external innovation, Ipsen rare disease external innovation, JLABS @ TMC leadership, and Bayer Co.Lab Cambridge head), focusing on sourcing translational science, building partnerships, and supporting startup growth. txlifescienceforum+2
Operational and portfolio leadership for incubators: In roles at JLABS @ TMC and Bayer Co.Lab Cambridge she was responsible for portfolio management, company onboarding, programming, and enabling access to laboratory infrastructure and corporate expertise for resident startups. txlifescienceforum+1
Scientist with a strong research and IP track record: Fiona holds a Ph.D. in Cell and Molecular Biology, has authored peer-reviewed research and review articles (including on ADCs and VHL-related vascular biology), and is named on patents related to LSD1 inhibitor combinations. nih+2
Advocate for inclusive and representative innovation: In public interviews and podcasts she emphasizes diversity and inclusive data practices in health innovation and the importance of building regional innovation ecosystems (notably in Houston while leading JLABS @ TMC). innovationmap+1

Work

Education

Writing

US10265279B2 - Combinations of LSD1 inhibitors for use in the treatment of solid tumors

April 1, 2019

Patent (US) claiming therapeutic combinations of LSD1 inhibitors with other active pharmaceutical ingredients for treating solid tumors; Fiona MACK is listed as an inventor/assignor on the patent record.

Favicon imagepatents.google.com

WO2017157825A1 - Combinations of LSD1 inhibitors for use in the treatment of solid tumors

September 1, 2017

International patent application corresponding to combinations of LSD1 inhibitors for treating solid tumors; Fiona MACK is listed as an inventor.

Favicon imagepatents.google.com

The next generation of antibody drug conjugates

January 1, 2014

Review of advances in antibody-drug conjugate (ADC) technology, including target selection, antibody engineering, linker/payload strategies, and clinical progress of ADCs.

Favicon imagepubmed.ncbi.nlm.nih.gov

pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition

Research article discussing the role of the von Hippel-Lindau (VHL) tumor suppressor protein in endothelial extracellular matrix assembly and vascular development; Fiona Mack is listed among contributing authors.

Favicon imagepmc.ncbi.nlm.nih.gov